» Articles » PMID: 23060454

Hyperlipidemia Offers Protection Against Leishmania Donovani Infection: Role of Membrane Cholesterol

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2012 Oct 13
PMID 23060454
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Leishmania donovani (LD), the causative agent of visceral leishmaniasis (VL), extracts membrane cholesterol from macrophages and disrupts lipid rafts, leading to their inability to stimulate T cells. Restoration of membrane cholesterol by liposomal delivery corrects the above defects and offers protection in infected hamsters. To reinforce further the protective role of cholesterol in VL, mice were either provided a high-cholesterol (atherogenic) diet or underwent statin treatment. Subsequent LD infection showed that an atherogenic diet is associated with protection, whereas hypocholesterolemia due to statin treatment confers susceptibility to the infection. This observation was validated in apolipoprotein E knockout mice (AE) mice that displayed intrinsic hypercholesterolemia with hepatic granuloma, production of host-protective cytokines, and expansion of antileishmanial CD8(+)IFN- γ (+) and CD8(+)IFN- γ (+)TNF- α (+) T cells in contrast to the wild-type C57BL/6 (BL/6) mice when infected with LD. Normal macrophages from AE mice (N-AE-MΦ) showed 3-fold higher membrane cholesterol coupled with increased fluorescence anisotropy (FA) compared with wild-type macrophage (N-BL/6-MΦ). Characterization of in vitro LD-infected AE macrophage (LD-AE-MΦ) revealed intact raft architecture and ability to stimulate T cells, which were compromised in LD-BL/6-MΦ. This study clearly indicates that hypercholesterolemia, induced intrinsically or extrinsically, can control the pathogenesis of VL by modulating immune repertoire in favor of the host.

Citing Articles

Oxidative stress-driven enhanced iron production and scavenging through Ferroportin reorientation worsens anemia in antimony-resistant Leishmania donovani infection.

Ghosh S, Chigicherla K, Dasgupta S, Goto Y, Mukherjee B PLoS Pathog. 2025; 21(1):e1012858.

PMID: 39888953 PMC: 11785346. DOI: 10.1371/journal.ppat.1012858.


Leishmania protein KMP-11 modulates cholesterol transport and membrane fluidity to facilitate host cell invasion.

Sannigrahi A, Ghosh S, Pradhan S, Jana P, Jawed J, Majumdar S EMBO Rep. 2024; 25(12):5561-5598.

PMID: 39482488 PMC: 11624268. DOI: 10.1038/s44319-024-00302-7.


Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease.

Benaim G, Paniz-Mondolfi A Biomolecules. 2024; 14(4).

PMID: 38672424 PMC: 11047903. DOI: 10.3390/biom14040406.


Non-Vesicular Lipid Transport Machinery in : Functional Implications in Host-Parasite Interaction.

Das K, Nozaki T Int J Mol Sci. 2023; 24(13).

PMID: 37445815 PMC: 10341546. DOI: 10.3390/ijms241310637.


Systems biology of autophagy in leishmanial infection and its diverse role in precision medicine.

Guhe V, Ingale P, Tambekar A, Singh S Front Mol Biosci. 2023; 10:1113249.

PMID: 37152895 PMC: 10160387. DOI: 10.3389/fmolb.2023.1113249.


References
1.
Tripathi P, Singh V, Naik S . Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol. 2007; 51(2):229-42. DOI: 10.1111/j.1574-695X.2007.00311.x. View

2.
Kaye P, Svensson M, Ato M, Maroof A, Polley R, Stager S . The immunopathology of experimental visceral leishmaniasis. Immunol Rev. 2004; 201:239-53. DOI: 10.1111/j.0105-2896.2004.00188.x. View

3.
Radhakrishnan A, Anderson T, McConnell H . Condensed complexes, rafts, and the chemical activity of cholesterol in membranes. Proc Natl Acad Sci U S A. 2000; 97(23):12422-7. PMC: 18778. DOI: 10.1073/pnas.220418097. View

4.
Gatfield J, Pieters J . Essential role for cholesterol in entry of mycobacteria into macrophages. Science. 2000; 288(5471):1647-50. DOI: 10.1126/science.288.5471.1647. View

5.
Titus R, Kelso A, Louis J . Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor/interferon. Clin Exp Immunol. 1984; 55(1):157-65. PMC: 1535781. View